drugset
drugset / Trial / NCT02005744

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

NCT02005744 ↗

Phase 1 Completed 26 enrolled Chong Kun Dang Pharmaceutical
Non-randomizedParallel-groupOpen-label

Summary

The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function.

Timeline

Start
2014-03
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lobeglitazone Small molecule 0.5 mg Oral

Indications

liver disorder